Visus Therapeutics Completes Enrollment in BRIO-I, a Phase 3 Clinical Trial of BRIMOCHOL™ PF for the Treatment of Presbyopia

SEATTLE & IRVINE, Calif.–(BUSINESS WIRE)– #VisusTx–Visus Therapeutics announced it completed enrollment in BRIO-I, a pivotal Phase 3 clinical trial of BRIMOCHOL™ PF for the treatment of presbyopia.